BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sunovion Pharmaceuticals Inc. to Lay Off Hundreds of Drug Reps in Consolidation Move


12/22/2011 7:14:44 AM

Boston Business Journal by Julie M. Donnelly, Reporter

Sunovion Pharmaceuticals, which is owned by Japanese drug maker Dainippon Sumitomo Pharma, has confirmed it will lay off an undisclosed number of sales representatives that are responsible for selling the company’s asthma drugs. The number of the layoffs was earlier reported to be near 300.

“Sunovion recently made the difficult decision to consolidate certain of its national Respiratory Sales Teams which resulted in a reduction in the number of field sales representatives detailing our respiratory brands,” spokeswoman Susan Alesina wrote in a statement. “This action was the result of Sunovion’s ongoing evaluation of how the company allocates its resources and implements promotional strategies across the entire portfolio of its marketed products. Sunovion believes this action will help to maximize the efficiency and effectiveness of our field sales efforts in serving asthma and allergy customer needs. I can not provide you with any additional details at this point in time.”

The website FierceBiotech, which first reported the cuts Wednesday, put the number of workers laid off at 288, citing an unnamed source.

The Marlborough, Mass-based company would not say how many workers are being let go, or where they are located. A spokesman for the Massachusetts Executive Office of Labor and Workforce development said that the company had not sent a letter to the state announcing any layoffs.

Sunovion has seven products that are currently approved by the FDA, including, Xopenex, Xopenex HFA and Alvesco for asthma, Lunesta for insomnia, Omnaris for allergies, Brovana for COPD, and Latuda for schizophrenia.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES